Gastrointestinal Neuroendocrine Tumours: A Single-Centre Experience
References
- Salyers WJ, Vega KJ, Munoz JC, Trotman BW, Tanev SS. Neuroendocrine tumors of the gastrointestinal tract: case reports and literature review. World J Gastrointest Oncol. 2014;6(8):301–310.
- Pinchot SN, Holen K, Sippel RS, Chen H. Carcinoid tumors. Oncologist. 2008;13(12):1255–1269.
- Rindi G, Klimstra DS, Abedi-Ardekani B, Asa SL, Bosman FT, Brambilla E, et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol. 2018;31(12):1770–1864.
- Ellis L, Shale MJ, Coleman MP. Carcinoid tumors of the gastrointestinal tract: trends in incidence in England since 1971. Am J Gastroenterol. 2010;105(12):2563–2569.
- Altekruse SF, Rosenfeld GE, Carrick DM, Pressman EJ, Schully SD, Mechanic LE, et al. SEER cancer registry biospecimen research: yesterday and tomorrow. Cancer Epidemiol Biomarkers Prev. 2014;23(12):2681–2687.
- Duggan MA, Anderson WF, Altekruse S, Penberthy L, Sherman ME. The Surveillance, Epidemiology, and End Results (SEER) Program and pathology: toward strengthening the critical relationship. Am J Surg Pathol. 2016;40(12):e94–e102.
- Yu JB, Gross CP, Wilson LD, Smith BD. NCI SEER public-use data: applications and limitations in oncology research. Oncology (Williston Park). 2009;23(3):288–295.
- Scherubl H, Streller B, Stabenow R, Herbst H, Hopfner M, Schwertner C, et al. Clinically detected gastroenteropancreatic neuroendocrine tumors are on the rise: epidemiological changes in Germany. World J Gastroenterol. 2013;19(47):9012–9019.
- Pavel M, Oberg K, Falconi M, Krenning EP, Sundin A, Perren A, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(7):844–860.
- Scott AT, Howe JR. Management of small bowel neuroendocrine tumors. J Oncol Pract. 2018;14(8):471–482.
- McCarthy DM. Proton pump inhibitor use, hypergastrinemia, and gastric carcinoids—what is the relationship? Int J Mol Sci. 2020;21(2):662.
- Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–1342.
- Wu L, Fu J, Wan L, Pan J, Lai S, Zhong J, et al. Survival outcomes and surgical intervention of small intestinal neuroendocrine tumors: a population based retrospective study. Oncotarget. 2017;8(3):4935–4947.
- Estrozi B, Bacchi CE. Neuroendocrine tumors involving the gastroenteropancreatic tract: a clinicopathological evaluation of 773 cases. Clinics (Sao Paulo). 2011;66(10):1671–1675.
- Oronsky B, Ma PC, Morgensztern D, Carter CA. Nothing but NET: a review of neuroendocrine tumors and carcinomas. Neoplasia. 2017;19(12):991–1002.
- Nozari N, Nikfam S, Nikmanesh A, Mohammadnejad M, Sotoudehmanesh R, Zamani F, et al. Clinical and pathological features of non-functional neuroendocrine tumors of pancreas: a report from Iran. Middle East J Dig Dis. 2014;6(3):151–155.
- Zeng YJ, Liu L, Wu H, Lai W, Cao JZ, Xu HY, et al. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine tumors: analysis from a single-institution. Asian Pac J Cancer Prev. 2013;14(10):5775–5781.
- Maggard MA, O’Connell JB, Ko CY. Updated population-based review of carcinoid tumors. Ann Surg. 2004;240(1):117–122.
- Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97(4):934–959.
- Quaedvlieg PF, Visser O, Lamers CB, Janssen-Heijen ML, Taal BG. Epidemiology and survival in patients with carcinoid disease in The Netherlands. An epidemiological study with 2391 patients. Ann Oncol. 2001;12(9):1295–1300.
- Gkolfinopoulos S, Tsapakidis K, Papadimitriou K, Papamichael D, Kountourakis P. Chromogranin A as a valid marker in oncology: clinical application or false hopes? World J Methodol. 2017;7(1):9–15.
- Cesar D, Zanatto RM, da Silva MV, Golcalves R, de Mello EL, de Jesus JP. Colon and rectum neuroendocrine tumors: experience of the National Cancer Institute in Brazil. Arq Bras Cir Dig. 2013;26(1):36–39.
- Sansone A, Lauretta R, Vottari S, Chiefari A, Barnabei A, Romanelli F, et al. Specific and non-specific biomarkers in neuroendocrine gastroenteropancreatic tumors. Cancers (Basel). 2019;11(8):1113.
- Tang H, Lu W, Li B, Meng X, Dong J. Influence of surgical margins on overall survival after resection of intrahepatic cholangiocarcinoma: a meta-analysis. Medicine (Baltimore). 2016;95(35):e4621.
- Pawlik TM, Scoggins CR, Zorzi D, Abdalla EK, Andres A, Eng C, et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg. 2005;241(5):715–22, discussion 22–24.
- Habal N, Sims C, Bilchik AJ. Gastrointestinal carcinoid tumors and second primary malignancies. J Surg Oncol. 2000;75(4):310–316.
- Dhruv S, Anwar S, Polavarapu A, Liliane D. Gastric carcinoid: the invisible tumor! Cureus. 2021;13(2):e13556.
Language: English
Page range: 3 - 8
Submitted on: Oct 31, 2021
Accepted on: Mar 30, 2022
Published on: Oct 15, 2022
Published by: Helenic Society of Medical Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 2 times per year
Related subjects:
© 2022 Hossein Yahyazadeh, Marzieh Beheshti, Sahel Valadan Tahbaz, published by Helenic Society of Medical Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.